ARH 46023

Drug Profile

ARH 46023

Alternative Names: ARH-460-23; ARVitamab™; H-460-23

Latest Information Update: 01 Feb 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ARIUS Research
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 01 Feb 2005 Discontinued - Preclinical for Cancer in Canada (Parenteral)
  • 19 Nov 2001 A preclinical study has been added to the Cancer adverse events and pharmacodynamics sections
  • 10 Sep 2001 Lead compounds are available for partnering(
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top